Eye shadow

Dark Storm Eyeshadow Palette

(283)
Select a shade:

Complimentary shipping on orders of $100 or more. Read the returns policy before you buy.

Need help? Contact us

The formula

A pressed-powder eyeshadow palette that pairs velvety mattes with luminous, pearled shimmers in one coordinated set. Highly pigmented and buildable, each shade lays down smooth, blends cleanly, and layers from a soft daytime wash to a fully defined evening eye. A jojoba and silicone binder keeps the powder soft and adherent, so the shades build and blend smoothly without patchiness.

Dark Storm is built around warm, smoky taupe and deeper neutral tones.

Finish: matte and shimmer · Coverage: buildable
Paraben-free. Cruelty-free. Made in North America.

The science

  • Up to 67% concentration evaluated

    Mica and Synthetic Fluorphlogopite confirmed safe as used in leave-on cosmetic formulations including eye-area products, with both ingredients covered under the same CIR safety assessment published in the International Journal of Toxicology.1

  • 51 triglycerides assessed

    Caprylic/Capric Triglyceride confirmed safe across all current cosmetic practices of use and concentration as part of a CIR comprehensive safety assessment covering 51 evaluated triglyceride esters with no skin sensitization identified at use-level concentrations.2

  • Measurable stratum corneum antioxidant activity

    Tocopherol confirmed to provide antioxidant protection in the skin's lipid-rich surface layer in leave-on cosmetic applications at concentrations below 1%, supporting formula stability and protection against oxidative degradation during wear.3

  • 7 FDA-approved colorants

    Every colorant across both matte and shimmer finish pans carries a specific FDA CFR permanent listing or batch certification exemption, with all seven approved for eye-area cosmetic use under applicable federal regulations.4

1Becker LC et al. International Journal of Toxicology, 2015. PMID: 26684795

2Fiume MZ et al. International Journal of Toxicology, 2022. DOI: 10.1177/10915818221123790

3Thiele JJ et al. Current Problems in Dermatology, 2001. DOI: 10.1159/000060651

4FDA 21 CFR 73.2575; FDA 21 CFR 73.2250; FDA 21 CFR 74.2052; FDA 21 CFR 74.2101; FDA 21 CFR 73.2299; FDA 21 CFR 74.2340; FDA 21 CFR 74.2705.

REVIEWS

Loading reviews…